All In Biotech

Drug Trial Radar · NCT07689188

Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

An Open-Label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

Mar 10, 2028

Study completion Dec 10, 2028

Sponsor

Lead sponsor
Harrison DermatologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study investigates the efficacy of topical roflumilast foam in patients with HS.

Conditions

  • Hidradenitis Suppurativa (HS)

Interventions

  • Roflumilast 0.3% topical foamDrug

    Roflumilast 0.3% topical foam applied once daily (QD) to all active hidradenitis suppurativa lesions for 16 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Abscess and Inflammatory Nodule (AN) Count at Week 16Time frame: Baseline and Week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Harrison Institute for Clinical Research at Harrison Dermatology

    Missouri City, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.